Phaseline

Targets › PD-L2

PD-L2: drug programs, companies and trials

1 program from 1 company in 3 trials: 2 Phase 1, 1 Phase 3; Oncology; next expected readout Nov 2026.

Open in Phaseline: the race on PD-L2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Akesopulocimab (AK109)
PD-L2 monoclonal antibody
PD-L2Phase 3Gastric and Gastroesophageal Junction Adenocarcinoma; Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma; Advanced Solid TumorNov 2026

Conditions

Gastric and Gastroesophageal Junction Adenocarcinoma (1) Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma (1) Advanced Solid Tumor (1)

Modalities

mixed (1)

Companies

Akeso (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.